Background: Hairy cell leukemia is a rare form of leukemia and has been rarely reported in African and pediatric population.
H airy cell leukemia (HCL) is a lymphoproliferative syndrome B that was described as a distinct clinic pathologic entity by Bouroncle et al in 1958. 1 The term "hairy" is related to the particular morphology of lymphocytes = tricho hair in Greek. Indeed, the cytoplasm of these cells that is present for extensions around the cell may look like hair. 2 It is characterized by mononuclear cells of B-lymphocyte origin in the peripheral blood that have prominent cytoplasmic projections staining with tartrateresistant acid phosphatase. This type of leukemia is a chronic lymphoid hemopathy generally observed among adults and has never been described in pediatric population. 2, 3 HCL has been mainly reported in whites and seems to be especially frequent in Ashkenazi Jewish males 2,3 with a rare occurrence in Asian population [4] [5] [6] and African population. [7] [8] [9] [10] A case of a child seen in our institution (University Hospital of Kinshasa, Kinshasa, the Democratic Republic of Congo) necessitated a literature review and a report.
CASE REPORT
A 4-year-old mixed origin child was transferred from Kisangani University Hospital in the North East of the Democratic Republic of Congo to the University of Kinshasa for the assessment of a suspected acute leukemia. The history of the present illness dates back about 5 weeks, characterized by prolonged fever, fatigue, and weakness. He is second in a family of 3 children. His elder brother and younger sister are still alive and in good health. His paternal grandfather was a white and died of multiple myeloma. He was taking any medication available. No findings suggest a particular risk period or an environment exposure. Physical examination revealed pallor, petechial hemorrhage, bruising gingival, microgeneralized lymphadenopathy, hepatomegaly, splenomegaly, abdominal pain, and weight loss.
Full blood count demonstrated leukocytosis (26Â 10 9 WBC/ L) with neutropenia (1.06Â 10 9 /L), no monocytes (0%), anemia (Hemoglobin, 4.3 g/dL), and moderate thrombocytopenia (platelets 63Â 10 9 /L). No blast cell was identified on peripheral smear. Bordet-Wasserman, human immunodeficiency virus, and hepatitis serology were negative. No plasmodium was found.
Bone marrow aspiration showed hypercellular marrow with rare magakaryocytes. Eighty-four percent of blast cells were type having the following characteristics: large cells of 10 to 25 mm diameter round or oval. The cytoplasm was variable and sometimes containing vacuoles, and budding were observed in clumps form of hair that could be quite long and slender, and the bulk of chromatin core variable had an oval shape, sometimes with 1 side cut either straight or lightly concave, sometimes we also observed the nucleoli (Fig. 1 ). The bone marrow was suggestive of HCL ( Fig. 2) .
During his hospitalization, the child did not receive any specific chemotherapy and splenectomy was contraindicated FIGURE 1. Abnormal lymphocytes with abundant cytoplasm, round nuclei, fine chromatin, and irregular projections of the cell membrane in microscopal examination of bone marrow.
because of a profound anemia and thrombocytopenia. Death occurred 1 week after admission to an array of severe infection and bleeding diathesis.
DISCUSSION
HCL is a rare form of leukemia. 2 HCL accounts for 2% to 3% of all leukemia cases with a low frequency in African population in the United States and in African countries. [7] [8] [9] [10] In Central Africa, the description of the disease is scarce. 10 In the Democratic Republic of Congo, this affection was not previously noted. Our observation is the first description of HCL in our population. As for other types of leukemia, the cause of HCL is not known. HCL is a disease that is usually present in adult population with males affected more than females. 2 The maximal frequency of the disease occurs in middle-aged men. The mean age is 52 years (range, 20 to 80 y). The age of presentation was slightly lower than usual in this patient who presented at 4 years of age. Only 1 case in pediatric population could be found with the use of available computer-assisted medical literature search programs. 11 Clinical features of our patient were similar to those described in the literature. 2, 12 Bone marrow depression was explained by the invasion with malign cells. Pathognomonic element of the disease is the presence of hairy cells in the bone marrow. On stained films of the bone marrow, the abnormal cells were round or oval, frequently with irregular windblown-appearing cell borders with pseudopod-like projections. The nucleus was round and occupied slightly more than half of the cell. On phase contrast microscopy, the living cells showed active projection of pseudopodia which were often fine, giving the cells their characteristic hairy appearance. This description was previously described for the diagnosis of HCL in the past. 12 This description was made for the diagnosis of HCL in context of low resources in Africa. 10 Cytochemistry and immunophenotyping confirm the diagnosis. These investigations were not performed because of technical reasons in our institution. In cytochemistry, hairy cells are "phosphatase acid positive, tartrate resistant" and in immunophenotyping, hairy cell is a B-lymphocyte cell expressing HLA-DR, CD20, and CD22 molecules. 2, 13 It is know that these cells typically infiltrate the bone marrow, the spleen, and to a lesser extent, the liver and lymph node. This involvement leads to splenomegaly with secondary consumption of red cells, platelets, and neutrophils. Pancytopenia characterizes the affection and hyperleukocytosis is rarely observed. Leukocyte formula shows neutropenia and the absence of monocytes. 2, 6, 12 Similar observations were described in our children.
As for other types of leukemia, the cause of HCL remains unclear. However, in recent studies, cytogenetic and molecular abnormalities were reported by the BRAF c. 1799 T > A p. Val 600 Glu V600E mutation in all patients with classic HCL. 14, 15 This discovery was an important step toward the knowledge about the pathogenesis of the disease.
Detection of V600E mutation of BRAF gene is the molecular marker of HCL. 16 Although immunophenotyping, cytogenetic, and molecular studies were not available to confirm the diagnosis, the child's bone marrow morphology and clinical course suggested this diagnosis.
There was no familial history of leukemia in our case. We have evoked the possibility of an unknown sporadic mutation because of the short-time history of his disease and young age. However, a question remains unclear about a potential link between multiple myeloma presented by his grandfather and HCL of this child.
An early diagnosis is important to ensure that the patient obtain maximum benefit from the newer therapeutic agents that greatly improved the prognosis in this rare disorder. 17 Splenectomy is beneficial in cases where anemia and thrombocytopenia are not very severe. In our case, severe anemia and profound thrombocytopenia had contraindicated splenectomy. In adults, the actual specific treatment consisted of the following molecules: interferon 2a and 2b, pentostatin, and cladribine. 17 Treatment with interferon leads to remission in 90% of patients. Once the treatment is interrupted, relapse occurs a year after. Treatment based on purines (pentostatin and cladribine) leads to a remission in 90% of cases. The risk of relapse is very rare compared with interferon. There is no data about children and our patient did not receive those specific treatments because the drugs were not available in our country. HCL in our child was found to be aggressive. Death occurred 1 week after admission. A recent study showed that a nonmutated status of HCL immunoglobin can be associated with an aggressive form of the disease. These previous descriptions suggest a central role of the tumor B-cell receptor in defining the outcome of HCL. 18 
Future Perspective
Facilities for genetic and molecular studies such as Cytochemistry and immunophenotyping are not readily available in the Democratic Republic of Congo. This situation limits understanding of the genetic disorder underlying most of hemopathies encountered in pediatric practice.
An implementation of molecular and genetic laboratories is advocacy in tertiary institutions of the Democratic Republic of Congo to elucidate particular cases for a contribution to knowledge and progress of science in tropical environment. Health determinants were different with geographical area. Physicians need to rise up to the challenges in the management of children with severe pathologies, such as leukemia, and be equipped to answer without unnecessary delay the usually burning questions in the minds of the parents, namely: What is this? What is the cause? Does it have any cure?
